Cargando…

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate

OBJECTIVE: To compare the tumor control in prostate cancer patients with oligo-metastasis following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone based on total prostate-specific antigen (tPSA) assessment. METHODS: Medical data of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xuwen, Xi, Haibo, Cheng, Xiaofeng, Yu, Yue, Zhang, Cheng, Wang, Gongxian, Zhou, Xiaochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951113/ https://www.ncbi.nlm.nih.gov/pubmed/36843605 http://dx.doi.org/10.3389/fendo.2023.1123934

Ejemplares similares

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
por: Jin, Di, et al.
Publicado: (2022)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients
por: Liu, Jinan, et al.
Publicado: (2013)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy
por: Zhenhao, Zeng, et al.
Publicado: (2022)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Safety first: evidence for delay of radical prostatectomy without use of androgen deprivation therapy during COVID-19
por: Sean Ong, Xuan Rui, et al.
Publicado: (2020)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy
por: Ouyang, Wei, et al.
Publicado: (2021)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital
por: Sangkum, Premsant, et al.
Publicado: (2021)

Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation
por: Kalaitzis, Christos, et al.
Publicado: (2014)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
por: Sato, Yuzuri Tsurumaki, et al.
Publicado: (2014)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis
por: Guo, Lijuan, et al.
Publicado: (2020)

The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy
por: Park, Jae Won, et al.
Publicado: (2020)

Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
por: Heesterman, Berdine L., et al.
Publicado: (2023)

Androgen deprivation modulates the inflammatory response induced by irradiation
por: Wu, Chun-Te, et al.
Publicado: (2009)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer
por: Choi, Se Young, et al.
Publicado: (2021)

The Impact of Exercise on Improving Body Composition and PSA in High-Risk Prostate Cancer Patients on Androgen-Deprivation Therapy
por: Lin, Yu-Ching, et al.
Publicado: (2022)

The Ocular Surface Characteristics in Prostate Cancer Patients Treated with Androgen Deprivation Therapy
por: Li, Weina, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
por: Park, Jae Won, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i8h4n6r4euu3d59j1i9k8v6j0b